Introduction
The multiplicity of treatments that have been tried in acute cerebral infarction reflects the ineffectiveness of current management.' Corticosteroids reduce cerebral oedema associated with brain tumours,2 and prevention and control of cerebral oedema in acute brain infarction might be expected to lessen further tissue damage. Infusion of low-molecular-weight dextran increases circulation in ischaemic brain infarction,3 and this might help ischaemic neurones to survive.
We have evaluated the effects of combined dexamethasone and low-molecular-weight dextran in acute brain infarction.
Patients and methods
Forty patients aged under 66 were studied over four weeks. All Dexamethasone, dextran 40, and placebo were in identical phials bearing the patient's number. We were unaware of the identity of the phials being used, the code being broken only after final evaluation of the patients' conditions. The active treatment was given as follows: dexamethasone, 10 mg intramuscularly initially, followed by 5 mg six-hourly for seven days, then tapering to zero over seven days (total dose 215 mg); dextran 40, a loading dose of 500 ml intravenously over one to two hours, followed by 500 ml/12 hours for 72 hours. Placebo was given in amounts identical with those of the active drugs-0 9% NaCl in place of dexamethasone, and 10% glucose in place of dextran 40 were no significant differences in the pretreatment neurological, mobility, or total scores between the two groups (tables II-IV).
In the acute phase after the stroke 11 patients in each group were bedridden, and four weeks after the stroke 15 patients in each group could walk. Fourteen patients in the active treatment group and 13 of the controls improved, and four and six patients in the two groups respectively were unchanged (table V). In the active treatment group, four of the 14 patients who improved and one of four who were unchanged suffered a reversible worsening of their initial neurological scores in the first days of treatment. Among the controls only one of the 13 patients who improved and none of those who were unchanged had such reversible worsening. This difference between the two groups is significant (P < 0 05).
Two patients in the active treatment group and one of the controls died in the first week. Necropsy showed massive cerebral oedema in all three. One further patient in the active treatment group died from infarction of the contralateral hemisphere on the 21st day after the initial stroke.
There were no significant differences in the initial or subsequent neurological, mobility, or total scores between the two groups (tables II-IV) or in the incremental changes of these scores.
After three days' treatment one patient in the active treatment group had a reversible psychotic episode lasting a couple of days. Deep patients in the active treatment group in the third week after the stroke. All were given anticoagulants; none experienced pulmonary embolism.
Discussion
This appears to be the first study of the combined effects of dexamethasone and low-molecular-weight dextran in the acute stage of brain infarction. The results must therefore be compared with those obtained with either dexamethasone or low-molecularweight dextran alone.
In a double-blind study, Patten et al5 found dexamethasone to be beneficial in acute stroke. But when cerebral haemorrhages are excluded the results are less convincing. Furthermore, they did not evaluate the level of consciousness, which is usually regarded as a sensitive index of cerebral oedema. The results of more recent studies4 6 do not support the use of dexamethasone in acute stroke.
In a double-blind study of 100 patients with acute stroke favourable effects were reported with low-molecular-weight dextran.7 This claim, however, was based solely on nearsignificant improvements in mentation, reflexes, and total neurological state, the degree of functional recovery of the patients being ignored. Later studies failed to show any beneficial effect of low-molecular-weight dextran.8 9 None of these studies presented unequivocal evidence that patients who might have been bedridden would have been able to achieve a wheelchair life, or that those who might only have been able to walk aided would have become independent. We have now failed to show any beneficial effects of the simultaneous use of dexamethasone and low-molecular-weight dextran in acute brain infarction. Two patients in our active treatment group and one of the controls died from severe brain oedema. The active treatment also failed to stop the progression of brain oedema after the stroke, as shown by the reversible worsening of the neurological deficit in five patients. The treatment did not change the natural history of the acute brain infarction, as shown by the similar improvement in neurological state and mobility in the active treatment and control groups. In the acute stage 11 patients in each group were bedridden, and at the end of four weeks 15 patients in each group could walk.
Our results do not support the combined use of dexamethasone and low-molecular-weight dextran in acute brain infarction.
